Compare AGNC Investment Corp (AGNC) vs Amgen, Inc. (AMGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGNC Investment Corp vs Amgen, Inc. — how do they compare? AGNC Investment Corp trades at $10.95 (market cap $12.91B), while Amgen, Inc. trades at $417.75 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 17.4× AGNC Investment Corp's market cap, and AGNC Investment Corp pays the higher dividend (13.22%). Which is the better fit depends on your goals.
| AGNC | AMGN | |
|---|---|---|
Market Cap | $12.91B | $224.14B |
Sector | Financials | Health |
52-Week High | $12.17 | $417.20 |
52-Week Low | $9.46 | $271.18 |
Dividend Yield | 13.22% | 2.43% |
Enterprise Value | — | $267.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGNC Investment Corp. trades at $10.76, down 0.74% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The mortgage REIT reported strong profitability with a net income margin of 94.38% and ROE of 21.67% for 2025, while recent earnings beat expectations in Q1 and Q2 2026. Analysts maintain a consensus price target of $11.30, with 31% recommending Buy, though the majority (60%) suggest Hold.
AGNC offers a high dividend yield, supported by consistent payouts, but faces risks from interest rate sensitivity and leveraged mortgage securities. Upside potential exists if stable spreads persist, yet the stock's valuation above book value requires careful monitoring of portfolio performance and macroeconomic conditions.
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
